MedPath

Influence of Cincalcet on Cognitive Functions in Healthy Human Subjects

Phase 2
Completed
Conditions
Memory Functions
Interventions
Drug: Placebo
Registration Number
NCT01599962
Lead Sponsor
Prof. Dominique de Quervain, MD
Brief Summary

To investigate the effects of the calcimimetic agent cinacalcet on cognitive functions in healthy humans.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
40
Inclusion Criteria
  • healthy
  • normotensive
  • native or fluent German-speaking
  • caucasian (European ancestry)
  • BMI between 19 and 27 kg/m2
Exclusion Criteria
  • acute or chronic psychiatric or somatic disorder
  • pathological ECG
  • Low serum calcium
  • known hypersensitivity to the IMP
  • pregnancy
  • breast-feading
  • long-term medication within last 3 months
  • smoking more than 3 cigarettes per day
  • seizures in participants and first degree relatives
  • concurrent participation in another study

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Sugar pillPlacebo-
CinacalcetCinacalcet-
Sugar pillCinacalcet-
Primary Outcome Measures
NameTimeMethod
Change of attention functions under cinacalcettwo study days within 10 days
Change of memory functions under cinacalcettwo testing days within 10 days
Secondary Outcome Measures
NameTimeMethod
Change of emotional state under cinacalcettwo study days within 10 days

Trial Locations

Locations (1)

University of Basel, Division of Cognitive Neuroscience

🇨🇭

Basel, Switzerland

© Copyright 2025. All Rights Reserved by MedPath